BR112014010658A2 - antígenos e vacinas direcionadas contra enterovírus humano - Google Patents

antígenos e vacinas direcionadas contra enterovírus humano

Info

Publication number
BR112014010658A2
BR112014010658A2 BR112014010658A BR112014010658A BR112014010658A2 BR 112014010658 A2 BR112014010658 A2 BR 112014010658A2 BR 112014010658 A BR112014010658 A BR 112014010658A BR 112014010658 A BR112014010658 A BR 112014010658A BR 112014010658 A2 BR112014010658 A2 BR 112014010658A2
Authority
BR
Brazil
Prior art keywords
antigens
directed against
against human
human enterovirus
vaccines directed
Prior art date
Application number
BR112014010658A
Other languages
English (en)
Portuguese (pt)
Inventor
Mary Jane Cardosa
Sharifah Binti Hamid
Mohamad Fakruddin Jamiluddin
Original Assignee
Sentinext Therapeutics Sdn Bhd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentinext Therapeutics Sdn Bhd filed Critical Sentinext Therapeutics Sdn Bhd
Publication of BR112014010658A2 publication Critical patent/BR112014010658A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112014010658A 2011-11-03 2012-11-01 antígenos e vacinas direcionadas contra enterovírus humano BR112014010658A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2011005318 2011-11-03
PCT/IB2012/003114 WO2013098655A2 (en) 2011-11-03 2012-11-01 Antigens and vaccines directed against human enteroviruses

Publications (1)

Publication Number Publication Date
BR112014010658A2 true BR112014010658A2 (pt) 2017-06-13

Family

ID=47215776

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010658A BR112014010658A2 (pt) 2011-11-03 2012-11-01 antígenos e vacinas direcionadas contra enterovírus humano

Country Status (16)

Country Link
US (3) US9987350B2 (enExample)
EP (2) EP2773372B1 (enExample)
JP (2) JP6190378B2 (enExample)
KR (3) KR102002103B1 (enExample)
CN (2) CN104093420B (enExample)
AU (1) AU2012360168C1 (enExample)
BR (1) BR112014010658A2 (enExample)
CA (1) CA2854594C (enExample)
CL (1) CL2014001160A1 (enExample)
HK (2) HK1245128A1 (enExample)
MX (2) MX363409B (enExample)
MY (1) MY172501A (enExample)
PH (2) PH12014501041B1 (enExample)
SG (1) SG11201401998VA (enExample)
TW (2) TWI571512B (enExample)
WO (1) WO2013098655A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700295B (zh) 2013-12-16 2020-08-01 馬來西亞商Ｍａｂ探索私人有限公司 對會感染人類之腸病毒具有專一性之抗體
DK4023249T3 (da) 2014-04-23 2025-01-13 Modernatx Inc Nukleinsyrevacciner
TWI686475B (zh) * 2014-04-29 2020-03-01 財團法人國家衛生研究院 對抗腸病毒感染之基於腺病毒載體之疫苗
CN111925423B (zh) * 2014-11-07 2022-08-19 普莱柯生物工程股份有限公司 一种抗o型口蹄疫的疫苗组合物及其制备方法和应用
CN106554965B (zh) * 2015-09-28 2019-08-27 斯澳生物科技（苏州）有限公司 用于制备ev71病毒样颗粒的核酸构建体和方法
CN105348391B (zh) * 2015-11-03 2019-06-28 李越希 埃可病毒6型vp1蛋白特异性抗原表位及其融合蛋白的制备、应用
CN105802923B (zh) * 2016-04-14 2019-07-16 中国科学院生物物理研究所 一种重组脊髓灰质炎病毒样颗粒及其制备方法与应用
SG10202010435XA (en) * 2016-04-22 2020-11-27 Integrated Research Associates Llc Improved method for producing virus like particles
US20190224304A1 (en) * 2016-10-07 2019-07-25 Sentinext Therapeutics Sdn Bhd Chimeric enterovirus virus-like particles
US20190247488A1 (en) 2016-10-07 2019-08-15 Sentinext Therapeutics Sdn Bhd Expression cassettes and methods for obtaining enterovirus virus-like particles
KR102091372B1 (ko) 2017-02-28 2020-05-27 대한민국 엔테로바이러스 71형 불활화 백신 및 이의 용도
CN108624601B (zh) * 2017-03-17 2023-08-11 中国科学院上海巴斯德研究所 酵母表达的柯萨奇病毒a10病毒样颗粒及其应用
SG11201913826QA (en) * 2017-07-03 2020-01-30 Bharat Biotech Int Ltd A synthetic polypeptide epitope based vaccine composition
CN108152511B (zh) * 2017-12-20 2019-01-04 广州瑞辉生物科技股份有限公司 柯萨奇A16病毒抗原多肽及其IgM抗体检测试剂盒
CN108424881B (zh) * 2018-03-23 2021-07-27 中国食品药品检定研究院 一株肠道病毒68型及其在制备ev-d68型感染动物中的应用
WO2020067027A1 (ja) * 2018-09-28 2020-04-02 一般財団法人阪大微生物病研究会 Ｖｌｐ発現ｃｈｏ細胞株の構築
CN110045105B (zh) * 2018-11-09 2022-04-26 广州市妇女儿童医疗中心 柯萨奇A16病毒IgA抗体量子点免疫荧光层析试纸条及试剂盒
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
CN110684781B (zh) * 2019-06-24 2021-05-28 四川农业大学 一种3型鸭甲肝病毒突变基因isa-a117c-t1142a及构建方法
CN112048004B (zh) * 2020-07-14 2021-10-22 桂林医学院 一种柯萨奇病毒b5型病毒样颗粒、其制备方法及应用
WO2022070210A1 (en) * 2020-09-29 2022-04-07 Bharat Biotech International Limited Stable formulations of low abundance enteroviruses vaccines and process of manufacture thereof
CN114107392A (zh) * 2021-11-22 2022-03-01 昆明理工大学 一种cvb5病毒类病毒样颗粒的制备方法
CN115010813B (zh) * 2022-05-19 2024-04-05 桂林医学院 一种肠道病毒71型病毒样颗粒、其制备方法及应用
CN116200348A (zh) * 2022-09-21 2023-06-02 武汉生物制品研究所有限责任公司 一种适应Vero细胞的柯萨奇病毒A10型毒株的构建方法及其应用
US11826418B1 (en) 2023-01-06 2023-11-28 King Faisal University Virus-like particle (VLP)-based vaccine against CVB4
WO2025029700A1 (en) * 2023-07-28 2025-02-06 Modernatx, Inc. Vlp enteroviral vaccines
CN117456519B (zh) * 2023-12-22 2024-03-12 江西科益高新技术有限公司 一种用于工控安全的仿真光电靶标装置及其仿真方法
CN120665160A (zh) * 2025-08-21 2025-09-19 国药中生生物技术研究院有限公司 肠道病毒71型的突变体及其病毒样颗粒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8102740A (nl) 1981-06-05 1983-01-03 Nederlanden Staat Virusvaccins en werkwijze ter bereiding daarvan.
WO2003046138A2 (en) * 2001-11-26 2003-06-05 Duke University Genetically stable expression vector
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
EP1479761A1 (en) * 2003-05-21 2004-11-24 PrimaGen Holding B.V. New enterovirus, vaccines, medicaments and diagnostic kits
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CN101365480B (zh) * 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
WO2008005777A2 (en) * 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
RU2528858C2 (ru) * 2008-08-28 2014-09-20 Новартис Аг Дисплей на поверхности клеток полипептидных изоформ на основе прочитывания терминирующего кодона
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
CN101831410B (zh) 2009-03-09 2013-04-17 北京工业大学 重组肠病毒71型病毒样颗粒的制备方法
GB0918375D0 (en) * 2009-10-20 2009-12-02 Animal Health Inst Construct
WO2012108840A1 (en) * 2011-02-08 2012-08-16 Temasek Life Sciences Laboratory Limited A novel expression cassette for efficient surface display of antigenic proteins

Also Published As

Publication number Publication date
PH12019500289A1 (en) 2020-02-17
KR101900460B1 (ko) 2018-11-08
EP3290050A1 (en) 2018-03-07
EP2773372A2 (en) 2014-09-10
TW201333195A (zh) 2013-08-16
CA2854594A1 (en) 2013-07-04
CN107441484A (zh) 2017-12-08
HK1251492B (en) 2019-10-25
MY172501A (en) 2019-11-27
JP6419271B2 (ja) 2018-11-07
MX363409B (es) 2019-03-20
CN104093420B (zh) 2017-07-28
PH12014501041A1 (en) 2014-08-04
US9987350B2 (en) 2018-06-05
US20180271971A1 (en) 2018-09-27
TW201716576A (zh) 2017-05-16
AU2012360168A2 (en) 2015-04-30
JP6190378B2 (ja) 2017-08-30
WO2013098655A9 (en) 2013-12-19
TWI626308B (zh) 2018-06-11
US10555997B2 (en) 2020-02-11
JP2014532691A (ja) 2014-12-08
US20150140027A1 (en) 2015-05-21
AU2012360168A1 (en) 2014-05-22
HK1202803A1 (en) 2015-10-09
EP3290050B1 (en) 2019-01-02
KR20180104201A (ko) 2018-09-19
CA2854594C (en) 2018-08-21
PH12014501041B1 (en) 2014-08-04
KR102002103B1 (ko) 2019-07-19
TWI571512B (zh) 2017-02-21
US10548964B2 (en) 2020-02-04
KR20170109700A (ko) 2017-09-29
AU2012360168B2 (en) 2017-06-22
WO2013098655A3 (en) 2013-09-12
KR20140096343A (ko) 2014-08-05
MX2014005315A (es) 2015-03-09
EP2773372B1 (en) 2018-12-26
AU2012360168C1 (en) 2017-09-28
JP2017226677A (ja) 2017-12-28
MX2018013782A (es) 2021-12-08
KR101782451B1 (ko) 2017-09-29
CN104093420A (zh) 2014-10-08
WO2013098655A2 (en) 2013-07-04
US20180243400A1 (en) 2018-08-30
SG11201401998VA (en) 2014-05-29
HK1245128A1 (zh) 2018-08-24
CL2014001160A1 (es) 2014-11-03

Similar Documents

Publication Publication Date Title
BR112014010658A2 (pt) antígenos e vacinas direcionadas contra enterovírus humano
IL285985A (en) Therapeutic nuclease compositions and methods
BR112014009634A2 (pt) preparação e agente terapêutico
IL248607A (en) Methods and compositions for immunization against virus
BR112013018469A2 (pt) dispositivos e métodos para tratamento de tecidos
BR112013022949A2 (pt) dispositivo e métodos de microagulha
BR112013022955A2 (pt) dispositivo e métodos de microagulha
LT2794654T (lt) Anti-phf-tau antikūnai ir jų panaudojimas
CO7071095A2 (es) Anticuerpos humanos anti-cd27, métodos, y usos
DK2521221T4 (da) Høreanordning og fremgangsmåde
DK2844286T3 (da) Lyofiliserede og vandige anti-CD40-antistofformuleringer
IL232262A (en) Therapeutic agents and uses thereof
PL2710033T3 (pl) Przeciwciała neutralizujące ludzkiego wirusa niedoboru odporności i sposoby ich stosowania
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
IL231777B (en) Antibodies against tl1a and uses thereof
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
BR112015004817A2 (pt) bioconjugados compreendendo antígenos modificados e seus usos
BR112014016240A2 (pt) dispositivo para tratamento de pele
CO6870003A2 (es) Vacunas bovinas y métodos
ZA201307641B (en) Human tissue factor antibody and uses thereof
SMT201600082B (it) Vaccino pcsk9
EP3494989C0 (en) COMPOSITE ANTIGEN SEQUENCES AND VACCINES
IL231120A0 (en) Implantable medical devices with increased immune tolerance, and methods for making and implanting
DK3205353T3 (da) Hurtig- og langtidsvirkende immunologisk terapeutisk middel

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]